Dr. Jan Oliver Huber, secretary general of the Association of the Pharmaceutical Industry in Austria, or PHARMIG, which represents 120 member companies and 95 percent of the medicinal product market in Austria, discusses the changing dynamics of the Austrian healthcare sector and its price referencing system. He also gives his insight into the potential of Austria as a clinical trials hub and what the EMA coming to Vienna will mean for the local healthcare ecosystem. Last time we met in 2012, the Austrian pharmaceutical industry was growing, despite facing some of the habitual challenges linked to mature markets. What have been the main events or changes during these last five years?
"We must work together and acknowledge that the price of a medicine reflects its impact for patients, economy and the society, especially when the therapy leads to a cure for a life changing condition."